Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial
Primary result · Days alive without antibioticsResult — go to the resultDifference 0.0 95% CI - 4.0 to 4.0Authors' conclusion
In ICU patients with CAP, a management strategy combining a mPCR and serum procalcitonin failed to reduce antibiotic exposure or improve outcomes on Day 28, compared to usual care.
Study context
- Population
- Non-immunocompromised adults (≥ 18 years) admitted to the intensive care unit (ICU) for community-acquired pneumonia385 evaluable (ITT)
- Participants
- 406 adults
- Comparison
- Intervention vs Control
- Primary endpoint
- Number of days alive without any antibiotic from enrollment to Day 28
- Follow-up
- Day 28
Methodological detailsmulticentre (n = 20), parallel-group, superiority, open-label, October 4, 2018, to March 3, 2022
- Multicentre (n = 20)
- Parallel-group
- Superiority
- Open-label
- October 4, 2018, to March 3, 2022
Primary result
Days alive without antibiotics
Difference
0.0
95% CI - 4.0 to 4.0
By group
As reported in the abstract
Further findings
| Outcome | Difference (days) (95% CI) |
|---|---|
| Antibiotic cumulative duration · Day 283 days shorter in the intervention group | 3 (- 5.1 to - 0.9) |
Safety
Serious adverse events
- Did not differ between groups
Original publication
Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial. Intensive Care Med. Published 15 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →